| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Soleno Therapeutics, Inc. (SLNO) has 9 insiders with recent SEC Form 4 filings, including 12 buys and 0 sells. SLNO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 569.5K | $30.19M | - | |
| CFO | 103.2K | $5.47M | - | |
| Other | 72.3K | $3.83M | - | |
| Other | 67.2K | $3.56M | - | |
| Other | 64.3K | $3.41M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2016 | Mario Ernest | Director, 10% Owner | Buy | 50,000 | $1.24 | $62,000.00 | +2.7% | |
| May 23, 2016 | Engelsen Steinar J | Director | Buy | 58,200 | $1.31 | $76,242.00 | +255.7% | |
| May 20, 2016 | Mario Ernest | Director | Buy | 48,806 | $1.18 | $57,639.07 | +1.3% | |
| May 20, 2016 | Engelsen Steinar J | Director | Buy | 18,821 | $1.23 | $23,139.41 | +107.2% | |
| May 13, 2016 | Anish Bhatnagar | President And CEO | Buy | 5,000 | $1.15 | $5,745.00 | +7.3% | |
| May 12, 2016 | O'Toole David D47 | See Remarks | Buy | 5,000 | $1.16 | $5,775.00 | +18.0% | |
| Nov 18, 2015 | Mario Ernest | Director, 10% Owner | Buy | 50,000 | $1.77 | $88,500.00 | +3.1% | |
| Nov 17, 2015 | O'Toole David D47 | SVP &Chief Financial Officer | Buy | 5,000 | $1.79 | $8,950.00 | +22.0% | |
| Sep 14, 2015 | O'Toole David D47 | SVP &Chief Financial Officer | Buy | 7,500 | $2.38 | $17,885.25 | +49.2% | |
| Sep 14, 2015 | Mario Ernest | Director, 10% Owner | Buy | 15,000 | $2.28 | $34,200.00 | +1.0% |